Status:
COMPLETED
Risperidone Treatment in Dually-Diagnosed Individuals - 2
Lead Sponsor:
National Institute on Drug Abuse (NIDA)
Collaborating Sponsors:
New York State Psychiatric Institute
Conditions:
Cocaine-Related Disorders
Eligibility:
All Genders
18-60 years
Phase:
PHASE2
Brief Summary
The purpose of this study is to evaluate the safety and efficacy of risperidone for cocaine dependence in individuals with schizophrenia/schizoaffective illness.
Eligibility Criteria
Please contact site for information.
Key Trial Info
Start Date :
Trial Type :
INTERVENTIONAL
End Date :
December 1 2001
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT00000267
End Date
December 1 2001
Last Update
January 12 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
New York State Psychiatric Institute
New York, New York, United States, 10032